Monday 22nd November 2021: A slam-dunking new partnership agreed between Randox Laboratories and Olimpia Milano

Global health diagnostics company Randox Laboratories has been announced as the official Diagnostics Partner of Olimpia Milano basketball team, in a new partnership spanning the remainder of the 2021/22 season.

Taking effect immediately, the new deal will see the sporting institution have access to Randox technology to perform a variety of health testing on Olimpia’s athletes and wider support staff. The cutting-edge health testing programme will include COVID PCR and lateral flow testing, a capability Randox already provides for international travel requirements and the UK’s National Testing Programme.

Adding to Randox’s existing portfolio of sports sponsorships which include the Great Britain and Northern Ireland Olympic and Paralympic Teams, the Aintree Racecourse Randox Grand National, and Sheffield United Football Club, the agreement with Olimpia Milano is the first venture into the European sports industry for the global testing company, which has an office in Rome from which it sells its pioneering tests and machines to hospitals, universities and veterinary centres across Italy.

Giulio Saule, Randox Sales Manager for North Italy, explained;

“Randox is tremendously proud to be associated with a sporting organisation as prestigious as Olimpia Milano and to have the opportunity to bring our testing capabilities, including COVID testing, out of the standard laboratory setting and on to the court, so that players and coaches may directly benefit from our world-leading diagnostic technologies.

“Our clinical tests and analysers have useful applications for sports science to help measure, predict and develop athletic performance, and so we look forward to working with the squad to not only ensure COVID-safe exercise and games, but to enhance their training plans for optimal results.”

Founded in 1982 in County Antrim by leading medical scientist Dr. Peter FitzGerald‎ CBE, Randox has been saving lives through early and accurate diagnosis for almost 40 years. Today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis through use of Randox products each year.

To achieve its goals the company is committed to an extensive research programme, which includes the investment of more than £300m in the development of its innovative biochip array technology which allows many tests to be run simultaneously, greatly improving the diagnostic power available to clinicians. The company currently employs more than 2000 people of over 40 different nationalities.

Dr. Peter FitzGerald, Managing Director of Randox Laboratories, is thrilled at the new Olimpia Milano partnership and expansion into the European sports industry, stating;

“We understand the importance of comprehensive and reliable testing within sport and furthermore the significant reach for our preventative health messaging when channelled through the power of sport. As a global market leader within the clinical diagnostics field, it was a ‘no-brainer’ for Randox to partner with a similarly ambitious sporting organisation leading the way in both the Lega Basket Serie A and the EuroLeague.

“We look forward to working alongside Olimpia Milano – working together to push the boundaries of healthcare and enhance team performance as the season progresses.”

Christos Stavropoulos, General Manager of Olimpia Milano, concluded;

“We are very excited for this new partnership with Randox, which has been well-known across the life sciences industry in Italy for many years but is now also a household name for its COVID testing laboratories which have grown to be one of the largest and most productive in Europe.  We are extremely impressed with their operation and look forward to working together as both organisations go from strength to strength in the years ahead.”

For further information please contact James Crilly;  james.crilly@randox.com / 028 9442 2413

Related Pages